Marksans Pharma Limited is a pharmaceutical holding company. The Company is engaged in the research, manufacturing and marketing of generic pharmaceutical formulations. The Company's product portfolio addresses various therapeutic segments, including Pain management, Cough and cold, Anti-diabetic, Cardiovascular system, Central nervous system, Antibiotic, Gastrointestinal, Anti-allergic and Miscellaneous. The Company undertakes research and development initiatives, and offers customer relationship management (CRM) services to global pharmaceutical companies. The Company has a manufacturing facility for the manufacture of oral solid tablets and soft gelatin capsules in Goa; a liquids/ointments/sachets manufacturing facility in Southport, the United Kingdom, and a solid oral dosages manufacturing facility in New York, the United States. It supplies products to approximately 20 countries. Its subsidiaries include Nova Pharmaceuticals Australasia Pty Ltd. and Marksans Pharma (UK) Limited.